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e connection between genomics, proteomics and 
metabolomics is evident in even the most simplistic of 
scientific models. Genes give rise to mRNA. Proteins are 
translated from mRNA and then proceed to carry out a 
myriad of functions within the cell, including the meta-
bolism of small molecules such as glucose and adenosine 
triphosphate. Not that many years ago, scientists used to 
study the ‘big 4’ biomolecules under the guise of genes, 
transcripts, protein and metabolites. e last decade of 
biomedical research, however, has been witness to the 
growth of the ‘omics’ industries. Genomics, trans crip-
tomics and proteomics have become core technologies 
within almost every major academic or industrial 
research program around the world. What was missing 
was the final piece of the omics puzzle: metabolomics.
Mass spectrometry or nuclear magnetic 
resonance?
From a technology perspective, metabolomics has come 
along at precisely the right time. e two major tech-
nologies used to gather metabolomics data, mass spec-
tro metry (MS) and nuclear magnetic resonance (NMR) 
spectroscopy, have both reached fantastic heights of data 
gathering capability [1,2]. Comparatively speaking, how-
ever, MS and NMR spectroscopy have their own specific 
advantages and disadvantages when conducting metabo-
lomic studies. e main advantage of MS is sensitivity, as 
state-of-the-art mass spectrometers can detect analytes 
routinely in the femtomolar to attomolar range. Coupling 
MS with liquid chromatography (LC) or gas chromato-
graphy (GC) enables the measurement of hundreds of 
individual species within a single sample. e combi na-
tion of mass accuracy and real-time tandem MS available 
with many mass spectrometers, along with increasingly 
comprehensive databases, is making the identification of 
these metabolites more routine. One of the major 
weaknesses of MS in metabolomics is quantification. e 
MS signal intensity of any compound is affected by the 
type of sample preparation used and its molecular 
environment. Adding known amounts of internal isotope-
labeled standards enables accurate quantification for 
specific molecules; however, this strategy is impractical 
for purely discovery-driven metabolomics research. Most 
studies rely on comparing peak area or intensity to locate 
differences in the relative abundance of specific 
metabolites between samples. However, these measure-
ments can suffer from a lack of accuracy and precision.
e major weaknesses of MS are the major strengths of 
NMR spectroscopy. e peak area of a compound in the 
NMR spectrum is directly related to the concentration of 
specific nuclei (for example, 1H, 13C), making quanti fi-
cation of compounds in a complex mixture very precise. 
A metabolite detected as being more abundant in a 
specific sample can be identified either through the 
resonance positions of its nuclei in the NMR spectrum, 
or through the application of various pulse-sequences 
such as total correlation spectroscopy, heteronuclear 
single quantum coherence and heteronuclear multiple 
bond correlation. Another underappreciated character of 
NMR spectroscopy is its versatility for analyzing 
metabolites in the liquid state (serum, urine and so on), 
in intact tissues (for example, tumors) or in vivo. 
Unfortunately, sensitivity, which is the major strength of 
MS, is the major weakness of NMR spectroscopy. 
Although cryogenically cooled probe technology, higher 
field-strength superconducting magnets [3] and minia tur-
ized radiofrequency coils [4] have increased sensitivity, 
NMR spectroscopy is still orders of magnitude less 
sensitive than MS.
While metabolomics is less mature than genomics and 
proteomics, it is already making a major impact in a wide 
variety of scientific areas, including newborn screening, 
toxicology, drug discovery, food safety and biomarker 
discovery (Figure 1). As with genomics and proteomics, 
most of the pressure will be on metabolomics to find 
biomarkers of diseases such as cancer. Investigators have 
already shown the potential promise of metabolomics in 
this area. For example, Sreekumar et al. [5] used LC-MS 
and GC-MS to profile 42 tissue, 110 urine and 110 plasma 
samples from patients affected with benign prostate 
disease, clinically localized prostate disease and 
metastatic disease. Not only were they able to distinguish 
these three conditions based on the NMR data, but they 
found that a specific metabolite, sarcosine, was highly © 2010 BioMed Central Ltd
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increased in concentration during prostate cancer 
progression to metastasis. This increased sarcosine level 
could be detected non­invasively in urine. In an ovarian 
cancer study, Dr Olivier Fiehn’s laboratory conducted a 
metabolomics screening of 66 invasive ovarian carcinoma 
tissues and 9 borderline tumors of the ovary [6]. Over 50 
identified metabolites were shown to differ significantly 
between the sample cohorts. Many of these metabolites 
play a role in purine and pyrimidine metabolism, glycero­
lipid metabolism and energy metabolism. The next 
challenge with this study, as with every biomarker dis­
covery study using omics technology, are to conduct 
validation studies to determine if any of the metabolites 
can be used to reliably diagnose the disease.
The future of metabolomics
Metabolomics has a unique opportunity to impact 
discovery­driven science in a way that genomics, trans­
criptomics and proteomics could not fully exploit. 
Metabolomics is maturing at a time when the other three 
omic technologies are much further advanced, and 
therefore we now have a greater opportunity to integrate 
metabolomics data with those obtained for the other ‘big 
4’ biomolecules. If we go back to our simplistic model of 
gene → transcript → protein → metabolite, our greatest 
chance in finding truly useful disease biomarkers will be 
studies that show correlation between biomolecules at all 
four levels. With genomic, transcriptomic and proteomic 
data collection and analysis further advanced, it seems 
logical for any metabolomics discovery study to add 
results from those whenever possible. Years of effort have 
demonstrated, particularly in the fields of transcriptomics 
and proteomics, that working in technological ‘silos’ is an 
inefficient way to solve challenging biological problems.
A goal of the omic technologies is to be able to apply 
them in a clinical setting to evaluate or monitor the 
health status of patients. Of the two major technologies 
utilized in metabolomics, MS is more likely than NMR 
Figure 1. Metabolomics of disease. Metabolomics technologies are making a major impact on a wide variety of scientific and clinical areas, 
including newborn screening, toxicology, drug discovery, food safety and biomarker discovery.  Please use the following link to access the 
interactive version of this graphic [7].
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spectroscopy to play a greater role in the clinic. MS is 
already being applied routinely in clinical and diagnostic 
laboratories. In its present role, the ability of MS to 
directly measure a specific metabolite(s) in a biological 
sample is employed using methods primarily built upon 
isotope­dilution­MS. While most clinical MS assays are 
conducted in reference laboratories, this scenario is likely 
to change over the next few years as mass spectrometers 
became a standard laboratory instrument and the 
number of scientists familiar with this technology con­
tinues to increase. While magnetic resonance imaging 
(MRI) is widely used within hospitals, it is not the same 
technology as the NMR spectroscopy described in this 
editorial.
The ability to translate discovery into assays that can be 
applied routinely within the clinic will have an enormous 
impact on public health. In particular, the cry for disease­
specific biomarkers continues to be heard, as healthcare 
professionals have been promised for over a decade that 
omic technologies would meet this need. Can metabo­
lomics be the science that finally conquers the biomarker 
discovery challenge? On its own, it is likely to have no 
more success than proteomics. On its own, it will flood 
the literature with hundreds of studies that publish 
hundreds of biomarkers that show potential but never 
graduate to validation studies. However, integrating data 
from genomic and/or proteomic studies that corroborate 
metabolomics findings will provide the evidence needed 
to confidently recognize those biomarkers that are worth 
the resources required for validation. The hope is that 
metabolomics can learn from the other omic techniques 
and not repeat many of the same mistakes that have been 
made in which a lot of data were collected but little 
information was gleaned.
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